Monaco Asset Management Sam Fate Therapeutics Inc Transaction History

Monaco Asset Management Sam

$677 Million
Q4 2024

A detailed history of Monaco Asset Management Sam transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Monaco Asset Management Sam holds 327,671 shares of FATE stock, worth $308,010. This represents 0.08% of its overall portfolio holdings.

Number of Shares

327,671

Previous 137,671 138.01%

Holding current value

$308,010

Previous $481,000 12.27%

% of portfolio

0.08%

Previous 0.07%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$1.61 - $3.35 $305,900 - $636,500	190,000 Added 138.01%	327,671 $540,000
Q3 2024 Nov 07, 2024	SELL	$3.12 - $5.57 $465,594 - $831,205	-149,229 Reduced 52.01%	137,671 $481,000
Q2 2024 Aug 07, 2024	SELL	$3.26 - $7.08 $97,490 - $211,727	-29,905 Reduced 9.44%	286,900 $941,000
Q1 2024 May 09, 2024	SELL	$3.54 - $8.35 $6.61 Million - $15.6 Million	-1,866,423 Reduced 85.49%	316,805 $2.33 Million
Q4 2023 Feb 07, 2024	BUY	$1.65 - $3.94 $553,218 - $1.32 Million	335,284 Added 18.14%	2,183,228 $8.17 Million
Q3 2023 Nov 07, 2023	BUY	$2.02 - $5.04 $1.7 Million - $4.25 Million	842,718 Added 83.83%	1,847,944 $3.92 Million
Q2 2023 Aug 08, 2023	BUY	$4.76 - $6.59 $166,281 - $230,208	34,933 Added 3.6%	1,005,226 $4.78 Million
Q1 2023 May 11, 2023	BUY	$4.24 - $11.12 $3.05 Million - $8.01 Million	720,293 Added 288.12%	970,293 $5.53 Million
Q4 2022 Jan 31, 2023	BUY	$9.86 - $23.83 $2.47 Million - $5.96 Million	250,000 New	250,000 $2.52 Million

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $91.2M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Monaco Asset Management Sam, based on Form 13F filings with the SEC.

News

Stay updated on Monaco Asset Management Sam with notifications on news.

Account

Monaco Asset Management Sam Fate Therapeutics Inc Transaction History